Comparation of EGFR-TKI (EGFR tyrosine kinase inhibitors) combination therapy and osimertinib for untreated EGFR-mutated advanced non-small cell lung cancers: A systematic review and network meta-analysis

EGFR-TKI (tyrosine kinase inhibitor) monotherapy has become the first-line treatment option for patients with EGFR-mutated non-small cell lung cancer (NSCLC). Prolonging the survival time, improving the progression-free survival of front-line treatment, and delaying the occurrence of drug resistance...

Descripción completa

Detalles Bibliográficos
Autores principales: Lei, Yang, Duan, Jia, Zhang, Qiong, Li, Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Research Article: Systematic Review and Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378737/
https://www.ncbi.nlm.nih.gov/pubmed/37505120
http://dx.doi.org/10.1097/MD.0000000000034483

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378737/
https://www.ncbi.nlm.nih.gov/pubmed/37505120
http://dx.doi.org/10.1097/MD.0000000000034483

Ejemplares similares